MV6: A Cyclic Peptide That Enhances Antibiotic Efficacy Against Acinetobacter baumannii
Author Information
Author(s): Roson-Calero Natalia, Lucas Jimmy, Gomis-Font María A., de Pedro-Jové Roger, Oliver Antonio, Ballesté-Delpierre Clara, Vila Jordi, Di Pietro Marisa, Baindara Piyush
Primary Institution: Barcelona Institute for Global Health (ISGlobal)
Hypothesis
Can the cyclic peptide MV6 enhance the efficacy of aminoglycosides against Acinetobacter baumannii?
Conclusion
MV6 enhances the effectiveness of netilmicin against Acinetobacter baumannii, despite lacking intrinsic antimicrobial activity.
Supporting Evidence
- MV6 showed a strong synergy with netilmicin, reducing its MIC significantly.
- MV6 lacks intrinsic antimicrobial activity, minimizing selective pressure.
- Mutations in efflux pump regulators were observed in resistant mutants.
- MV6 reduced the mutant prevention concentration of netilmicin by 16-fold.
- Statistically significant overexpression of the adeB gene was correlated with increased netilmicin MIC.
Takeaway
MV6 is a special peptide that helps an antibiotic called netilmicin work better against a tough germ called Acinetobacter baumannii.
Methodology
The study assessed MV6's activity through antimicrobial susceptibility testing, synergy evaluation using checkerboard assays, and whole-genome sequencing of spontaneous mutants.
Limitations
The study's sample size was limited, and further research is needed to explore the relationship between MV6 and various resistance mechanisms.
Participant Demographics
Clinical isolates of Acinetobacter baumannii from patients in hospitals.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website